Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
agatolimod sodium + trastuzumab
- Development stage
- Preclinical
- Lead developer
- Pfizer
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous, Intravenous
01
Overview
Agatolimod sodium is a synthetic 24-mer oligonucleotide containing three CpG motifs that selectively targets Toll-like receptor 9 (TLR9), activating dendritic and B cells and stimulating cytotoxic T cell and antibody responses against tumor cells bearing tumor antigens[5][7]. Trastuzumab is a monoclonal antibody targeting HER2/neu, which is overexpressed in certain breast cancers. The combination of agatolimod sodium with trastuzumab has been investigated as an immunotherapeutic approach to treat patients with locally advanced or metastatic breast cancer, aiming to enhance immune-mediated antitumor activity alongside direct HER2 inhibition[1][5].
- Brand names
- trastuzumab
- Other names
- agatolimod tricosasodium saltHerceptin (for trastuzumab, but not for the combination)CpG-7909 + trastuzumab
02
Targets
TLR9 (Toll-like receptor 9)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on agatolimod sodium + trastuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on agatolimod sodium + trastuzumab.